Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 41Withdrawn 4Terminated 4Active not recruiting 4Recruiting 3

Sponsor Class

OTHER 80INDUSTRY 23NIH 8OTHER_GOV 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Breast Neoplasms 18Prostatic Neoplasms 15Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Multiple Myeloma 10Melanoma 9Pancreatic Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lung Neoplasms 5Hodgkin Disease 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Hematologic Neoplasms 4Brain Neoplasms 4Teratoma 3Smoldering Multiple Myeloma 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms, Germ Cell and Embryonal 3Neoplasm Metastasis 3Malignant Solid Neoplasm 3HIV Infections 3Fallopian Tube Neoplasms 3Colonic Neoplasms 3

Interventions

pegaspargase 2merphos 2calaspargase pegol 2Vincristine 2Specimen Handling 2Methotrexate 2Leucovorin 2Inotuzumab Ozogamicin 2Cytarabine 2Cyclophosphamide 2Biopsy 2Asparaginase 2prednylidene 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1blinatumomab 1azathiopurine 1auricularum 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Thioguanine 1Spinal Puncture 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1Mercaptopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × NETWORK × Burkitt Lymphoma × Clear all
NCT02981628 2026-06-05

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06635330 2024-10-10

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Kara Yakhteh Tajhiz Azma Company

Phase 1/2 Recruiting
5 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡